Pharmafile Logo
Pharmafocus logo
Advanced Search

Valeant

Showing 15 posts of 90 posts found.

stocks3

Losses and profit forecast cuts send shares tumbling again at Valeant

June 8, 2016
Research and Development, Sales and Marketing Shares, Valeant, cut, forecast, tumbling

Valeant Pharmaceuticals has published its results for the first quarter, which has seen the firm post a net loss of …

News
dollars_medicines

Valeant announces expanded discounts for Nitropress and Isuprel

May 17, 2016
Manufacturing and Production, Sales and Marketing Isuprel, Nitropress, Valeant, discounts

Valeant Pharmaceuticals (NYSE: VRX) has stepped up its public relations campaign with an announcement of expanded discounts for Nitropress (nitroprusside) …

News
papa

Valeant announces new patient access and pricing committee; vows to correct past “mistakes”

May 6, 2016
Medical Communications, Sales and Marketing Valeant, joseph papa, new committee, patient access, price gouging, pricing

Valeant (NYSE: VRX) has announced the establishment of a new patient access and pricing committee that will be responsible for …

News
eyeimagenotext-1

Valeant’s Bausch + Lomb teams up with IBM for cataract surgery app

May 5, 2016
Research and Development Bausch and Lomb, Valeant, app, cataract, cataract surgery, ibm, ipad, iphone, surgeons

IBM (NYSE: IBM) and Bausch + Lomb, a wholly owned subsidiary of Valeant (NYSE: VRX), have announced a partnership that …

News
bill_ackman

Big investor hits back at critics as Valeant’s war of words gathers pace

May 3, 2016
Manufacturing and Production, Sales and Marketing Valeant, ackman, allegations, buffett, practices, price gouging, price rises, scandal

Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …

News
j

Valeant’s outgoing boss tells Senate committee he “regrets” drug price rises

April 28, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Senate, Valeant, admits, aggressive, committee, drug price, pearson, rises

Outgoing Valeant (NYSE: VRX) boss, Michael Pearson, expressed regret at the way his company conducted operations to a US Senate …

News
joseph_papa

Valeant names Joseph Papa as new chief executive officer

April 25, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Chairman, Valeant, joseph papa, new, new ceo, papa, pearson

Valeant Pharmaceuticals has announced that Joseph C. Papa will succeed Michael Pearson as chairman and chief executive officer of the …

Appointment
stocks2

Valeant receives further default notices due to its delayed 10-K filing

April 25, 2016
Medical Communications, Sales and Marketing Valeant, default, risk, trouble, worry

Valeant Pharmaceuticals has issued a statement detailing that they have received additional notices of default under indentures due to its …

News
stocks1

Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…

April 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market

Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …

Feature
stocks2

Valeant bondholders issue notice to default

April 13, 2016
Research and Development, Sales and Marketing Valeant, bondholders, default, fears, possibility

Valeant (NYSE: VRX) has issued a statement detailing plans from some of its bondholders to call a default because of …

News
figures_charts

Valeant’s ad hoc committee closes chapter on Philidor controversy

April 5, 2016
Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, ad hoc, ad hoc committee

Valeant (NYSE: VRX) has announced that the ad hoc committee of the board of directors has finished its review of …

News
stats_data

Timeline of turmoil – Valeant Pharmaceuticals’ troubled March 2016

April 4, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Share price, Valeant, fall, month from hell, timeline, turmoil

As far as months go, March 2016 couldn’t have gone much worse for Valeant Pharmaceuticals. The Canada-based company has been …

Feature
valeant

Valeant’s outgoing CEO subpoenaed by US congressional committee

March 29, 2016
Medical Communications, Research and Development Drug pricing, Michael Pearson, US, Valeant, committee, pearson, pharma, price hikes, senate aging committee, subpoena, subpoenaed

The US Senate Aging Committee has announced the issuing of a subpoena to the outgoing CEO of Valeant Pharmaceuticals, Michael …

News
mylan_plus_hero_720x510

Mylan launches generic of Valeant’s Ultram in the US

March 29, 2016
Manufacturing and Production, Sales and Marketing FDA, Mylan, Valeant, abbreviate new drug application, generic, pain, tramadol, ultram

Mylan (NASDAQ, TASE: MYL) has announced the launch of its generic version of Valeant’s Ultram tablets in the US. The …

News
valeant_sign

Valeant CEO Pearson to leave company

March 21, 2016
Michael Pearson, Valeant

Valeant (NYSE:VRX) has announced that it has begun the search for a new CEO, confirming that Michael Pearson is to …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025